tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2022 Apr 11;10(4):586.
doi: 10.3390/vaccines10040586.
Safety and Immunogenicity of COVID-19 BBIBP-CorV Vaccine in Children 3-12 Years Old
Khaled Greish[SUP] 1 [/SUP], Abdulla Alawadhi[SUP] 2 3 [/SUP], Ahmed Jaradat[SUP] 1 [/SUP], Amer Almarabheh[SUP] 1 [/SUP], Marwa AlMadhi[SUP] 3 4 [/SUP], Jaleela Jawad[SUP] 3 5 [/SUP], Basma Alsaffar[SUP] 6 [/SUP], Ejlal Alalawi[SUP] 6 [/SUP], Adel Alsayyad[SUP] 6 [/SUP], Afaf Merza[SUP] 6 [/SUP], Batool Alalawi[SUP] 6 [/SUP], Donia Qayed[SUP] 2 [/SUP], Ahmed Humaidan[SUP] 3 [/SUP], Manaf Al Qahtani[SUP] 2 3 7 [/SUP]
Affiliations
Abstract
Background and objectives: In the current COVID-19 pandemic, children below the age of 12 could manifest COVID-19 symptoms and serve as a reservoir for the virus in the community. The present study was conducted to evaluate the reactogenicity, and immunogenicity of BBIBP-CorV, prior to involving this age group in the vaccination program in the kingdom of Bahrain.
Subjects and methods: The study included 582 children from 3 to 12 years old of Bahraini and non-Bahraini nationality, all of which contributed to the reactogenicity study. Of those, 401 contributed to the immunogenicity study. All children received 2 doses of BBIBP-CorV inactivated virus 3 weeks apart. To assess reactogenicity, children were followed up for 5 weeks to evaluate any vaccine-related adverse events (AE). To assess immunogenicity, blood was collected on day 0 and day 35 to assess antibody titer against S, N, and neutralizing antibody.
Results: Of the 582 participants, (45.4%) were female, (54.61%) were male, with 49% in 9-12 age group. Of the 401 children contributing to the immunogenicity study, 274 (68.3%) had no prior exposure to COVID-19. The overall incidence of AE was 27.7%. No significant difference was found among different age groups. The most frequent AE was local (at the injection site) and occurred in 16% of children, followed by fever in 9.3%. No serious adverse events were reported. The Seroconversion rate was 100% among children with no prior exposure to COVID-19. Children with previous COVID-19 exposure had higher averages of anti-S (2379 U/mL compared to 409.1), anti-N (177.6 U/mL compared to 30.9) and neutralizing antibody (93.7 U/mL compared to 77.1) than children with no prior exposure at day 35.
Conclusions: Two doses of COVID-19 BBIBP-CorV on the subjects aged between 3 to 12 has good safety and tolerance and can induce an effective immune response and neutralizing antibody titer.
Keywords: BBIBP-CorV; COVID-19; anti-nucleocapsid; children 3–12 years old; neutralizing antibody; the anti-spike.
. 2022 Apr 11;10(4):586.
doi: 10.3390/vaccines10040586.
Safety and Immunogenicity of COVID-19 BBIBP-CorV Vaccine in Children 3-12 Years Old
Khaled Greish[SUP] 1 [/SUP], Abdulla Alawadhi[SUP] 2 3 [/SUP], Ahmed Jaradat[SUP] 1 [/SUP], Amer Almarabheh[SUP] 1 [/SUP], Marwa AlMadhi[SUP] 3 4 [/SUP], Jaleela Jawad[SUP] 3 5 [/SUP], Basma Alsaffar[SUP] 6 [/SUP], Ejlal Alalawi[SUP] 6 [/SUP], Adel Alsayyad[SUP] 6 [/SUP], Afaf Merza[SUP] 6 [/SUP], Batool Alalawi[SUP] 6 [/SUP], Donia Qayed[SUP] 2 [/SUP], Ahmed Humaidan[SUP] 3 [/SUP], Manaf Al Qahtani[SUP] 2 3 7 [/SUP]
Affiliations
- PMID: 35455335
- PMCID: PMC9028114
- DOI: 10.3390/vaccines10040586
Abstract
Background and objectives: In the current COVID-19 pandemic, children below the age of 12 could manifest COVID-19 symptoms and serve as a reservoir for the virus in the community. The present study was conducted to evaluate the reactogenicity, and immunogenicity of BBIBP-CorV, prior to involving this age group in the vaccination program in the kingdom of Bahrain.
Subjects and methods: The study included 582 children from 3 to 12 years old of Bahraini and non-Bahraini nationality, all of which contributed to the reactogenicity study. Of those, 401 contributed to the immunogenicity study. All children received 2 doses of BBIBP-CorV inactivated virus 3 weeks apart. To assess reactogenicity, children were followed up for 5 weeks to evaluate any vaccine-related adverse events (AE). To assess immunogenicity, blood was collected on day 0 and day 35 to assess antibody titer against S, N, and neutralizing antibody.
Results: Of the 582 participants, (45.4%) were female, (54.61%) were male, with 49% in 9-12 age group. Of the 401 children contributing to the immunogenicity study, 274 (68.3%) had no prior exposure to COVID-19. The overall incidence of AE was 27.7%. No significant difference was found among different age groups. The most frequent AE was local (at the injection site) and occurred in 16% of children, followed by fever in 9.3%. No serious adverse events were reported. The Seroconversion rate was 100% among children with no prior exposure to COVID-19. Children with previous COVID-19 exposure had higher averages of anti-S (2379 U/mL compared to 409.1), anti-N (177.6 U/mL compared to 30.9) and neutralizing antibody (93.7 U/mL compared to 77.1) than children with no prior exposure at day 35.
Conclusions: Two doses of COVID-19 BBIBP-CorV on the subjects aged between 3 to 12 has good safety and tolerance and can induce an effective immune response and neutralizing antibody titer.
Keywords: BBIBP-CorV; COVID-19; anti-nucleocapsid; children 3–12 years old; neutralizing antibody; the anti-spike.